Brava Diagnostics is developing a portfolio of in vitro diagnostic tests for medical settings where lab-quality results are vital in making time-critical decisions. Brava is developing a NextGen test for heart attack for the emergency department. Our first cardiac marker test will be a high-sensitivity troponin (hs-cTn) test that will enable faster diagnosis of heart attack or rule-out/discharge of low-risk patients. Safe discharge reduces unnecessary hospital admissions, reduces crowding in the emergency department and cuts costs to the healthcare system significantly.
Emergency physicians need precise lab results, ideally within 15 minutes, to guide treatment or safe discharge for patients with chest pain. New guidelines from the European Society of Cardiology and the American College of Cardiology are driving the shift to high-sensitivity troponin assays (hs-cTn). Central lab tests suffer from turnaround time of more than an hour. Point-of-care (POC) assays are widely used, but the, care team must compromise performance for speed. Neither lab nor POC tests meet the need.
Brava can fill this large market gap with a high-sensitivity troponin test that delivers lab-quality performance at the point-of-care in 15 minutes.
The LightDeck Platform
The LightDeck technology platform consists of a portable fluorescence analyzer and disposable, multiplex test cartridges. The test procedure is simple, so that an untrained user can perform testing at the point-of-care. Each cartridge contains 36 discreet analysis zones that enables replicate measurements for improved performance, simultaneously running multiple related tests for diagnosis or rule-out of a specific condition, and internal quality control to ensure quality and safety.
Download our Fact Sheet
Download a 2-page strategy summary.
Schedule a meeting